Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines.

FEBS open bio - 1 Jul 2026

Huart Camille, Van den Abbeel Manon, Schifflers Christoph, Bouhjar Karim, Scarmelotto Andrea, Khelfi Alexis, Wera Anne-Catherine, Michiels Carine

Abstract excerpt

Several anticancer treatments have been shown to activate the DNA damage repair pathway but also, in some cases, to lead to therapy-induced senescence. Senescent cells can either exert protumoral or antitumoral effects. However, it remains poorly characterized which treatments lead to a senescent state. Our findings identify Talazoparib, a PARP1 inhibitor, as the most potent inducer of senescence in nonsmall cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Cellular Senescence

Share to Phthalazines

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 41714887
DOI: 10.1002/2211-5463.70206
PMCID: PMC13327013

Genes

PARP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines.PMID 41714887Read ↗

Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263Semantic proximity Read ↗

Tumor Cell Recovery from Senescence Induced by Radiation with PARP InhibitionSemantic proximity Read ↗

Novel senolytic and senescence-suppressing compounds overcome senescence-driven chemoresistance in NSCLCSemantic proximity Read ↗

Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescenceSemantic proximity Read ↗

The PARP inhibitor olaparib promotes senescence in murine macrophagesSemantic proximity Read ↗

Melatonin regulates PARP 1 to control the senescence‐associated secretory phenotype ( SASP ) in human fetal lung fibroblast cellsSemantic proximity Read ↗

DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor SensitivitySemantic proximity Read ↗

Mortalin sensitizes human cancer cells to MKT-077-induced senescenceSemantic proximity Read ↗

MiR-34a modulates ionizing radiation-induced senescence in lung cancer cellsSemantic proximity Read ↗

Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cellsSemantic proximity Read ↗

Olaparib-Induced Senescence Is Bypassed through G2–M Checkpoint Override in Olaparib-Resistant Prostate CancerSemantic proximity Read ↗

New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small MoleculesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.